Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
May 03 2024 - 3:00AM
Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance
Agreement for US Market
Press release, Helsinki, 3 May 2024, 10 AM (EEST)
Nexstim, Inc. and Inomed Inc. Enter into Strategic
Alliance Agreement for US Market
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that
Nexstim, Inc. has signed a non-exclusive strategic alliance
agreement with Inomed Inc. for the purpose of strengthening the
collaboration of Marketing, Sales, and Application Support between
both companies in the United States.
Both Nexstim and Inomed will attend the American Association of
Neurological Surgeons (AANS) Annual Scientific Meeting in Chicago,
IL this week, where both companies will present their products and
service offerings to leading neurosurgeons from the US and around
the world. Nexstim team can be found at booth no. 721 and Inomed at
booth no. 914.
In addition, Nexstim invites all those interested in nTMS brain
mapping to a Lunch and Learn event held at the AANS Meeting on
Saturday May 4, 2024 at 12:30 pm at B1 # 1343. The Lunch and Learn
will be covering recent advancements in non-invasive brain mapping
with Profs. Hugues Duffau, Sujit Prabhu and Sandro Krieg. Admission
is free, but as seats tend to go quickly, we advise attendees to
arrive early. Lunch will be provided.
Further information is available on the website
www.nexstim.com, or by contacting:
Mikko Karvinen, CEO+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for pre-surgical mapping of the speech and motor
cortices of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
About Inomed
Inomed is a leading medical device manufacturer,
developing sophisticated products for neuro-diagnostics,
neurosurgical interventions and related therapies. The origins of
Inomed lay in intraoperative monitoring of neurological function
and the company has been recognized by the “Top 100” Society as one
of the most innovative medium-sized German companies, engaging in
research partnerships with universities and specialized
institutes.
Headquartered in Emmendingen, near the city of
Freiburg-Breisgau in Germany, Inomed employs more than 400 people
worldwide, including a research and development department with
subject matter experts from the fields of biology, medicine,
informatics, mechanical engineering and the humanities, working
together with medical experts from hospitals, clinics and other
research partners. Inomed’s ultimate goal is to provide the most
effective tools to the clinician, thereby improving outcomes and
helping to enhance quality of life for patients.
More information available at
https://www.en.inomed.com/.
- Nexstim Plc_Press release_Inomed_03052024_FINAL